For the third time, NovAliX is organising its Biophysics in Drug Discovery Conference. This new edition will cover current hot topics including cryo-EM and introduce new features.
Because of the ever growing success of the two first editions, we will change the venue and relocate the event to the newly renovated Strasbourg Convention Centre.
The use of biophysical methods in drug discovery is rapidly increasing and the field is in constant evolution. Many pharmaceutical companies have set up in-house biophysical platforms to speed up the target-to-candidate process and improve the quality of small-molecule therapeutics through a better understanding of their interactions with their targets. Academic labs involved in early-stage drug discovery also heavily rely on biophysical techniques.
The third edition of the conference intends again to bring together biophysicists and medicinal chemists, the synergy between their disciplines being key to deliver better drugs on a shorter timeline.
This year, the conference will include the following sessions :
- Biophysics for Biotherapeutics Discovery / Selection / Characterisation / Optimisation
- Biophysics for Challenging Targets (Membrane Proteins, Multi-protein or Dynamic Complexes, Intrinsically Disordered Proteins…)
- Cellular Biophysics : Translation from Biochemical to Biological Systems
- Emerging Technologies (XFELs, Single-molecule Techniques, FTIR, MALDI-imaging MS…)
- Computational Biophysics
- Cryo-EM (Special Focus of the conference)
and we are pleased to announce that Sandra Cowan-Jacob (Novartis Institutes for Biomedical Research, Basel) will deliver the Keynote Lecture.
This time, the Scientific Programme will be completed by a Workshop on cryo-EM, Exhibitor short presentations and a Poster Session.